News Related to Severe Neutropenia

Related coverage linked through entity extraction aliases.

CAR-T toxicity management shifts toward phenotype- and mechanism-based intervention

Apr 24, 2026

CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.

FDA Approves Filkri, Accord BioPharma's Biosimilar to Neupogen

Jan 16, 2026

The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.